Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in obesity-related HFpEF
NL-OMON51952Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing Semaglutide with Placebo (2 arms). Primary endpoints: Change in Kansas City Cardiomyopathy Questionnaire clinical summary score and Change in body weight. Started Apr 2021; status: active, not recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on NL-OMON51952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51952.